Cannabis therapeutics and the future of neurology

93Citations
Citations of this article
569Readers
Mendeley users who have this article in their library.

Abstract

Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes. While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain. This review will examine the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), and cannabis terpenoids in the putative treatment of five syndromes, currently labeled recalcitrant to therapeutic success, and wherein improved pharmacological intervention is required: intractable epilepsy, brain tumors, Parkinson disease (PD), Alzheimer disease (AD) and traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE). Current basic science and clinical investigations support the safety and efficacy of such interventions in treatment of these currently intractable conditions, that in some cases share pathological processes, and the plausibility of interventions that harness endocannabinoid mechanisms, whether mediated via direct activity on CB1 and CB2 (tetrahydrocannabinol, THC, caryophyllene), peroxisome proliferator-activated receptor-gamma (PPARγ; THCA), 5-HT1A (CBD, CBDA) or even nutritional approaches utilizing prebiotics and probiotics. The inherent polypharmaceutical properties of cannabis botanicals offer distinct advantages over the current single-target pharmaceutical model and portend to revolutionize neurological treatment into a new reality of effective interventional and even preventative treatment.

References Powered by Scopus

Trial of cannabidiol for drug-resistant seizures in the dravet syndrome

1179Citations
N/AReaders
Get full text

Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

990Citations
N/AReaders
Get full text

Colonic bacterial composition in Parkinson's disease

986Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cannabinoids: Therapeutic Use in Clinical Practice

125Citations
N/AReaders
Get full text

Beyond THC and endocannabinoids

115Citations
N/AReaders
Get full text

Unconventional high-value products from microalgae: A review

96Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Russo, E. B. (2018). Cannabis therapeutics and the future of neurology. Frontiers in Integrative Neuroscience, 12. https://doi.org/10.3389/fnint.2018.00051

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 159

61%

Researcher 62

24%

Professor / Associate Prof. 26

10%

Lecturer / Post doc 12

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 81

40%

Neuroscience 43

21%

Pharmacology, Toxicology and Pharmaceut... 42

21%

Agricultural and Biological Sciences 37

18%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
Social Media
Shares, Likes & Comments: 3335

Save time finding and organizing research with Mendeley

Sign up for free